common/neoplasms

BACKGROUND OF THE INVENTION More than half of all human cancers are associated with one or more alterations in the tumor suppressor gene TP53 (1-4). Many premalignant lesions, a subset of malignant clones, and germlines of families prone to cancer are characterized by the presence of one wild-type

CROSS RELATED APPLICATIONS This application claims the benefit of Singapore Serial No. 10201506227V, filed Aug. 6, 2015, the contents of which are incorporated herein by reference. FIELD OF THE INVENTION The present invention relates to antibodies that bind to interleukin 2 receptor .beta.

BACKGROUND OF THE INVENTION This invention relates to identification of a new common antigen of colorectal and mucinous ovarian tumors (COTA) and to a process for isolating the same. This invention also relates to clinical application of COTA and anti-COTA antibodies in detection and diagnosis of

CROSS-REFERENCE TO RELATED APPLICATION This application is a national stage of the international application PCT/FR03/00970, filed March 27, 2003, which claims benefit of the application FR 02/03888, filed Mar. 28, 2002. The present invention relates to peptides representing shared epitopes of tumor

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the fields of genetics and molecular biology. More particular the invention relates to the identification of a gene that is involved in Bardet-Biedl Syndrome (BBS), designated here as BBS1. Defects in this gene

FIELD AND BACKGROUND OF THE INVENTION The present invention relates to methods of treating cancer using antibodies directed against p53 mutant proteins. The tumor suppressor gene p53 inhibits tumor growth primarily via induction of apoptosis. Mutations in the p53 tumor suppressor gene are the most

FIELD AND BACKGROUND OF THE INVENTION The present invention relates to methods of treating cancer using antibodies directed against p53 mutant proteins. The tumor suppressor gene p53 inhibits tumor growth primarily via induction of apoptosis. Mutations in the p53 tumor suppressor gene are the most

FIELD OF INVENTION The present invention relates to a method for treating cancer using an anti-cancer compound. More particularly, said anti-cancer compound is an anti-cervical-cancer compound. The present invention has a specific application in treating human cervical cancer. BACKGROUND OF

BACKGROUND OF THE INVENTION (a) Field of the Invention The invention relates to the use of antisense oligonucleotides directed against specific cellular receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, hypereosinophilia or atopic diseases

BACKGROUND OF THE INVENTION (a) Field of the Invention The invention relates to the use of antisense oligonucleotides directed against specific cellular receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, hypereosinophilia or atopic diseases

FIELD OF THE INVENTION The invention relates to the use of antisense oligonucleotides directed against specific cellular receptors, alone or in combination, in order to inhibit general inflammation, including inflammation associated with asthma, COPD, allergy, Cystic fibrosis (CF), and

BACKGROUND OF THE INVENTION The present invention generally relates to breast tumor screening devices and methods and, more particularly, is concerned with an in situ tumor temperature profile measuring probe and a method of using the probe. The early detection of tumors, which is the principal

BACKGROUND OF THE INVENTION The present invention generally relates to breast tumor screening devices and methods and, more particularly, is concerned with an in situ tumor temperature profile measuring probe and a method of using the probe. The early detection of tumors, which is the principal

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the national stage of International Patent Application No. PCT/US2014/20714, filed Mar. 14, 2014, which claims priority to, and the benefit of International Patent Application No. PCT/CN2013/072638, filed on Mar. 14, 2013, each of which is

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the provision of novel means for the diagnosis and therapy of cancers characterized by overexpression of gene products from the myc family. These means essentially include the use of monoclonal antibodies